Best Australian Shares To Buy For Long Term

Best Australian Shares to Buy for Long-Term in Volatile Markets

Volatile markets act like a dual edged sword. While they succeed in shaking the weak kneed, suave investors hound such an opportunity to acquire quality stocks at a discount. The bargain for such stocks, that deserve a place in buy and hold forever category, is often short lived.

The rattled markets throw many such stocks out of favour temporarily which offer seasoned players a chance to build long term wealth creating portfolio. 

Some top Australian shares to consider for long-term investment are

ResMed Inc. (ASX: RMD)

has delivered a strong performance for the financial year that ended on June 2025. The company reported its net income to rise by an impressive 37% to $1.401 billion from $1.021 billion in the previous financial year. This was on the back of a 10% increase in revenue which reached $5.146 billion compared to $4.685 billion in fiscal 2024. EBITDA and operating income also showed improvements that were supported by growth in both their Sleep and Breathing Health segment and Residential Care Software segment with revenue growth of 10% in both areas. Key drivers included increased device and mask sales, operational efficiencies and the integration of recent acquisitions like VirtuOx. The firm maintained a strong margin profile with a gross margin of 59.4%, improved from 56.7%. Customer growth and geographic diversification remain significant with sales distributed globally but with a focus on the United States, Europe, Asia and Latin America.

Pro Medicus Limited (ASX: PME)

has reported a strong Financial Year 2025 with revenue of $213.0 million which was up 31.9%. The company also reported underlying profit before tax to increase by 40.0% to $163.3 million. Net profit rose 39.2% to $115.2 million with cash and financial assets growing to $210.7 million. The company remains debt free and declared a fully franked final dividend of 30 cents per share. Strong contract wins totaling over $520 million including major deals with US healthcare providers such as Trinity Health, Duly Health and University of Kentucky underpin future growth.

Xero Limited (ASX: XRO)

delivered a strong Financial Year 2025 with revenue growing 23% to NZ$2.103 billion. Adjusted EBITDA also increased 22% to NZ$641 million. The company achieved a Rule of 40 outcome of 44.3% demonstrating balanced growth and profitability across its global markets. Subscriber numbers grew 10% on an underlying basis to 4.41 million while average revenue per user increased 11%. Xero continues to execute its FY25-27 “Winning on Purpose” strategy focused on its 3x3 growth pillars across Australia, UK and the US.

WiseTech Global Limited (ASX: WTC)

has reported a strong FY25 financial performance with total revenue rising 14% to USD 778.7 million and underlying NPAT increasing 30% to USD 241.8 million. CargoWise revenue grew 18% to USD 682.2 million which was driven by existing and new customers including significant Large Global Freight Forwarder rollouts. EBITDA excluding e2open M&A costs rose 26% to USD 409.5 million with an EBITDA margin of 53%. The company declared a 24% higher final dividend of 7.7 cents per share.

(Source: Company Announcements)